Affinity Asset Advisors’s Vaxcyte PCVX Stock Holding History

Affinity Asset Advisors’s Portfolio PCVX Stock Details PCVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-125,000	Closed	-$4.5M	–	116
2025 Q3	$4.5M	Hold	125,000	–	–	0.39%	56
2025 Q2	$4.06M	Buy	125,000 +100,000	+400%	+$3.28M	0.56%	45
2025 Q1	$944K	Hold	25,000	–	–	0.09%	83
2024 Q4	$2.05M	Sell	25,000 -25,000	-50%	-$2.48M	0.27%	58
2024 Q3	$5.71M	Sell	50,000 -10,000	-17%	-$901K	0.78%	41
2024 Q2	$4.53M	Sell	60,000 -20,000	-25%	-$1.36M	0.52%	45
2024 Q1	$5.46M	Buy	80,000 +55,000	+220%	+$3.81M	0.68%	45
2023 Q4	$1.57M	Hold	25,000	–	–	0.29%	59
2023 Q3	$1.27M	Buy	25,000 +11,077	+80%	+$546K	0.36%	51
2023 Q2	$695K	Sell	13,923 -48,300	-78%	-$2.29M	0.24%	59
2023 Q1	$2.33M	Buy	62,223 +2,223	+4%	+$94.3K	0.77%	37
2022 Q4	$2.88M	Buy	+60,000	New	+$2.35M	1.13%	29
2021 Q4	–	Sell	-50,000	Closed	-$1.27M	–	69
2021 Q3	$1.27M	Hold	50,000	–	–	0.32%	52
2021 Q2	$1.13M	Buy	50,000 +20,000	+67%	+$409K	0.4%	52
2021 Q1	$593K	Hold	30,000	–	–	0.2%	61
2020 Q4	$797K	Buy	+30,000	New	+$1.12M	0.42%	48

Other funds holding PCVX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Affinity Asset Advisors's PCVX Position: Q4 2025 in Review

Affinity Asset Advisors sold out of Vaxcyte (PCVX) in Q4 2025, closing a stake of 125,000 shares — an estimated $4.5M sold.

Affinity Asset Advisors first reported a position in PCVX in Q4 2020 and held it in 16 quarters. The position peaked at $5.71M in Q3 2024. 295 funds tracked by Wall St. Rank hold PCVX as of Q4 2025.

Affinity Asset Advisors reported no remaining Vaxcyte position as of Q4 2025 after selling out during the quarter.
Affinity Asset Advisors sold 125,000 Vaxcyte shares in Q4 2025, an estimated $4.5M.
Affinity Asset Advisors first reported a position in Vaxcyte in Q4 2020 and held it in 16 quarters.
Affinity Asset Advisors's Vaxcyte position peaked at $5.71M in Q3 2024.
295 funds tracked by Wall St. Rank held Vaxcyte as of Q4 2025.

Based on Affinity Asset Advisors's 13F filing for Q4 2025, filed 13 Feb 2026.